Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Cet article passe en revue les travaux récents sur les mécanismes de résistance aux thérapies ciblant la voie de signalisation du récepteur des androgènes pour le traitement des patients atteints d'un cancer de la prostate résistant à la castration
During the past 10 years, preclinical studies implicating sustained androgen receptor (AR) signalling as the primary driver of castration-resistant prostate cancer (CRPC) have led to the development of novel agents targeting the AR pathway that are now in widespread clinical use. These drugs prolong the survival of patients with late-stage prostate cancer but are not curative. In this Review, we highlight emerging mechanisms of acquired resistance to these contemporary therapies, which fall into the three broad categories of restored AR signalling, AR bypass signalling and complete AR independence. This diverse range of resistance mechanisms presents new challenges for long-term disease control, which may be addressable through early use of combination therapies guided by recent insights from genomic landscape studies of CRPC.